Snyder LA - Search Results

1

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

Zhu X, Fujita M, Snyder LA, Okada H. Zhu X, et al. Among authors: snyder la. J Neurooncol. 2011 Aug;104(1):83-92. doi: 10.1007/s11060-010-0473-5. Epub 2010 Nov 30. J Neurooncol. 2011. PMID: 21116835 Free PMC article.

2

Premetastatic soil and prevention of breast cancer brain metastasis.

Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H. Liu Y, et al. Among authors: snyder la. Neuro Oncol. 2013 Jul;15(7):891-903. doi: 10.1093/neuonc/not031. Epub 2013 Apr 17. Neuro Oncol. 2013. PMID: 23595625 Free PMC article.

3

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P, Sikic BI. Moisan F, et al. Among authors: snyder la. Mol Oncol. 2014 Oct;8(7):1231-9. doi: 10.1016/j.molonc.2014.03.016. Epub 2014 Apr 18. Mol Oncol. 2014. PMID: 24816187 Free PMC article.

4

Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888.

Obmolova G, Teplyakov A, Malia TJ, Grygiel TL, Sweet R, Snyder LA, Gilliland GL. Obmolova G, et al. Among authors: snyder la. Mol Immunol. 2012 Jun;51(2):227-33. doi: 10.1016/j.molimm.2012.03.022. Epub 2012 Apr 7. Mol Immunol. 2012. PMID: 22487721

5

Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies.

Tsui P, Das A, Whitaker B, Tornetta M, Stowell N, Kesavan P, Kaiser E, Lacy ER, Yan L, Snyder LA, Sweet R. Tsui P, et al. Among authors: snyder la. Hum Antibodies. 2007;16(3-4):117-25. Hum Antibodies. 2007. PMID: 18334747

6

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. Loberg RD, et al. Among authors: snyder la. Cancer Res. 2007 Oct 1;67(19):9417-24. doi: 10.1158/0008-5472.CAN-07-1286. Cancer Res. 2007. PMID: 17909051

7

A review of antibody therapeutics and antibody-related technologies for oncology.

Scallon BJ, Snyder LA, Anderson GM, Chen Q, Yan L, Weiner LM, Nakada MT. Scallon BJ, et al. Among authors: snyder la. J Immunother. 2006 Jul-Aug;29(4):351-64. doi: 10.1097/01.cji.0000199196.97845.c3. J Immunother. 2006. PMID: 16799330 Review. No abstract available.

8

Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.

Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, Barajas JM, Snyder LA, Frankel WL, Caligiuri MA, Jacob ST, Yu J, Ghoshal K. Teng KY, et al. Among authors: snyder la. Mol Cancer Ther. 2017 Feb;16(2):312-322. doi: 10.1158/1535-7163.MCT-16-0124. Epub 2016 Dec 15. Mol Cancer Ther. 2017. PMID: 27980102 Free PMC article.

9

Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.

Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, McNally LR, Buchsbaum DJ, Rosenthal EL. Dean NR, et al. Among authors: snyder la. Clin Cancer Res. 2009 Jun 15;15(12):4058-65. doi: 10.1158/1078-0432.CCR-09-0212. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509148 Free PMC article.

10

Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.

Villarreal DO, Chin D, Smith MA, Luistro LL, Snyder LA. Villarreal DO, et al. Among authors: snyder la. Oncotarget. 2017 Jun 13;8(24):39117-39130. doi: 10.18632/oncotarget.16605. Oncotarget. 2017. PMID: 28388572 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page